Prevalence of Deficiency of Vitamin D in Critically Ill Patients
Investigating the Prevalence of Deficiency of Vitamin D in Critically Ill Patients and Its Effects on the Prognosis
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Studies have revealed that the serum level of 25-hydroxyvitamin D, as known as calcidiol, is low in critically ill patients. The prevalence ranges from 26 to 82%. 25-hydroxyvitamin D deficiency is associated with longer ICU stay, higher medical cost and higher death rate in septic patients. 25-hydroxyvitamin D is a kind of hormone related to bone and mineral metabolism. Moreover, the receptors were found in almost all cells, and it is related to immune system, cytokine release, cellular proliferation and differentiation, angiogenesis, and muscular energy. The main source is skin metabolism triggered by sunshine and food consumption. It is subsequently converted to calcifediol in the liver and then calcitriol in the kidney (the active form). Its serum level is regulated by parathyroid hormone and serum calcium and phosphate. The critically ill patients are deprived of sunshine, suffered from poor nutrition support, impaired liver and kidney function, higher rate of consumption, and are under higher risk of deficiency. Nowadays, the studies about 25-hydroxyvitamin D in ICU patients were conducted mostly in Europe and America. There is no large-scale study in Taiwan or Asia. A randomized controlled study from Austria has shown large dose supply in patients with 25-hydroxyvitamin D deficiency could decrease the mortality.
The object of this multi-center study is to investigate the prevalence of 25-hydroxyvitamin D deficiency, the risk factors and the correlation with outcomes. The results could be a step-stone for future randomized controlled studies.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Taipei, Taïwan, 100
- National Taiwan University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- All ICU patients
Exclusion Criteria:
- 1, Less than 20 years 2, BMI < 18 kg/m^2 3, Had large dose vit D within previous four weeks (over 3000 IU per day) 4, ICU admission within previous three months 5, Have disease affecting vit D level, calcium metabolism, bone metabolism such as parathyroid disease, Rickets, liver cirrhosis child C 6, Communication difficulty
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Group 1
Patients admitted to ICU less than 48 hours and the anticipated stay is less than 5 days.
Take blood sample on the day of enrollment.
|
|
Group 2
Patients admitted to ICU less than 48 hours and the anticipated stay is longer than 5 days.
Take blood sample on the day of enrollment, 7th, 14th, 21st, and 28th.
Stop blood sample once exit.
|
|
Group 3
Patients admitted to ICU 3~7 days.
Take blood sample on the day of enrollment.
|
|
Group 4
Patients admitted to ICU 8~14 days.
Take blood sample on the day of enrollment.
|
|
Group 5
Patients admitted to ICU 15~28 days.
Take blood sample on the day of enrollment.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The prevalence of Vitamin D deficiency
Délai: 1 day at enrollment
|
Investigate the prevalence of vitamin D deficiency among groups
|
1 day at enrollment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Difference of mortality on 28th and 90th day in group 2
Délai: 90 days
|
Compare the mortality of 28th and 90th day of patients with vitamin D deficiency and patients without vitamin D deficiency in group 2
|
90 days
|
|
Difference of mortality on 28th and 90th day in group 3, 4, and 5
Délai: 90 days
|
Compare the mortality of 28th and 90th day of patients with vitamin D deficiency and patients without vitamin D deficiency in group 3, 4, and 5
|
90 days
|
|
Serial changes of serum vitamin D levels in group 2
Délai: 28 days
|
investigate the serum vitamin D levels at different time points in group 2
|
28 days
|
|
Difference of 28-day ventialtor-free days
Délai: 28 days
|
Compare the 28-day ventialtor-free days of patients with vitamin D deficiency and patients without vitamin D deficiency for all groups
|
28 days
|
|
Difference of 28-day ICU-free days
Délai: 28 days
|
Compare the 28-day ICU-free days of patients with vitamin D deficiency and patients without vitamin D deficiency for all groups
|
28 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Chung-Wei Chen, MD, Far Eastern Memorial Hospital
- Chercheur principal: Li-Kuo Kuo, MD, Mackay Memorial Hospital
- Chercheur principal: Kuo-Ching Yuan, MD, Taipei Medical University Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 201805087RINB
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .